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Background: The comparative efficacy and safety profiles of systemic antifungal 2 
drugs for tinea capitis in children remain unclear. 3 
Objective: To assess the effects of systemic antifungal drugs for tinea capitis in children. 4 
Methods: We used standard Cochrane methodological procedures.  5 
Results: We included 25 randomized controlled trials (RCTs) with 4449 participants. 6 
Terbinafine and griseofulvin had similar effects for children with mixed Trichophyton 7 
and Microsporum infections (risk ratio [RR] 1.08, 95% confidence interval [CI] 0.94 to 8 
1.24). Terbinafine was better than griseofulvin for complete cure of T. tonsurans 9 
infections (RR 1.47; 95% CI 1.22 to 1.77); griseofulvin was better than terbinafine for 10 
complete cure of infections caused solely by Microsporum species (RR 0.68; 95% CI 11 
0.53 to 0.86). Compared with griseofulvin or terbinafine, itraconazole and fluconazole 12 
had similar effects against Trichophyton infections 13 
Limitations: All included studies were at unclear or high risk of bias. Lower quality 14 
evidence resulted in a lower confidence in the estimate of effect. Significant clinical 15 
heterogeneity existed across studies.  16 
Conclusions: Griseofulvin or terbinafine are both effective; terbinafine works better 17 
for T. tonsurans and griseofulvin for M. canis infections. Itraconazole and fluconazole 18 
are alternative but not optimal choices for Trichophyton infections. Optimal regimens 19 
of antifungal agents need further studies. 20 
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Keywords: Tinea capitis; children; systemic antifungal therapy; systematic review; 21 
Cochrane; treatment  22 
3 
 
CAPSULE SUMMARY 23 
 Systemic antifungal therapy is the key intervention for tinea capitis. 24 
 Griseofulvin and terbinafine are the first-line agents of choice; terbinafine and 25 
griseofulvin are better for Trichophyton tonsurans and Microsporum canis, 26 
respectively. Itraconazole and fluconazole are alternative treatments. 27 




Tinea capitis is caused by dermatophyte fungi (usually Trichophyton or Microsporum 30 
species; e.g. T. tonsurans, T. mentagrophytes, T. violaceum, M. canis, and M. audouini, 31 
etc.). 1 It affects healthy preadolescent children and rarely occurs in adults., 1 It is 32 
common in countries of all income levels around the world; however, the prevalence 33 
varies across study populations within different geographical areas. 2 A fungal kerion 34 
describes an abscess-like mass, which if left untreated can lead to scarring and 35 
permanent hair loss. 36 
Antifungal agents are the primary interventions for treating tinea capitis (e.g., 37 
griseofulvin, terbinafine, ketoconazole, fluconazole, and itraconazole). They are widely 38 
used in clinical practice. 1, 3 The comparative efficacy and safety profiles for these 39 
agents with different dosages or durations of treatment remain unclear. We conducted 40 
this literature review to address the efficacy and safety of systemic antifungal drugs 41 
for tinea capitis in children. 42 
METHODS 43 
Our analysis is based on a Cochrane review most recently updated in the Cochrane 44 
Library 2016, issue 5 (www.thecochranelibrary.com). 4 Full details of the methods and 45 
all the included studies are available from the Cochrane review. 46 
Inclusion criteria 47 
We included randomized controlled trials (RCTs) that were conducted in children with 48 
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normal immunity and with tinea capitis confirmed by microscopy, growth of 49 
dermatophytes in culture or both. All regimens of systemic antifungal therapies for 50 
tinea capitis were included. 51 
Searches 52 
We searched the following databases up to November 2015: MEDLINE via Ovid (from 53 
1946), EMBASE via Ovid (from 1974), LILACS (from 1982), CINAHL via EBSCO (from 54 
1981), CENTRAL (2015, issue 10), and the Cochrane Skin Group Specialized Register. 55 
We also searched five trials registers. We hand searched the bibliographies of included 56 
and excluded studies for further references to relevant trials and we contacted 57 
principal investigators for missing data. 58 
Data extraction 59 
Two review authors independently extracted the information from the included RCTs, 60 
and another author checked the data extraction forms for accuracy. Discrepancies 61 
were resolved by discussion. 62 
Outcomes  63 
Based on the protocol of the review, two primary outcomes were identified: 1) the 64 
proportion of participants with complete cure (i.e., clinical and mycological cure); and 65 
2) the frequency and type of adverse events. We also assessed four secondary 66 
outcomes: 1) the proportion of participants with clinical cure only; 2) measurement of 67 
recurrence of the condition after the end of the intervention period; 3) percentage of 68 
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drop-outs; and 4) the time taken to cure. We present the results of primary outcomes 69 
in this abridged version. 70 
Two review authors independently assessed the risk of bias for each included RCT 71 
according to the methods recommended in Sections 8.9 to 8.15 of the Cochrane 72 
Handbook for Systematic Reviews of Interventions. 5 The Cochrane risk of bias domains 73 
for each RCT were rated as low risk of bias, high risk of bias, and unclear risk of bias 74 
accordingly.  75 
We presented dichotomous outcomes as risk ratios (RR) with 95% confidence intervals 76 
(CI). We presented the only continuous outcome, the time taken to cure, as the mean 77 
with standard differences. When we identified clinically similar RCTs we pooled 78 
dichotomous data into a meta-analysis using random-effects model (Mantel-Haenszel 79 
method) in Revman 5.3 software. 6 We performed subgroup analyses according to 80 
dermatophyte species variation and duration of treatment, if possible. The duration of 81 
treatment was categorized into three groups: 1) short term (closest to 2 weeks, but 82 
between 1 and 4 weeks); 2) medium term (closest to 6 weeks, but between 5 and 8 83 
weeks); and 3) long term (closest to 12 weeks, but between 9 and 14 weeks). 84 
RESULTS 85 
We included a total of 25 RCTs 7-31 with 4449 participants (Fig. 1). All were parallel 86 
group studies, and ten had a multi-arm design. Sample size varied from 13 to 1549 87 
participants. Each of the 25 studies reported the types of fungus cultured. 88 
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Trichophyton species predominated over Microsporum species in the included studies; 89 
T. tonsurans and M. canis caused infection in the highest proportion of participants. 90 
The overall quality of included RCTs was moderate or low and in some cases ‘very low’ 91 
according to the Grading of Recommendations Assessment, Development and 92 
Evaluation (GRADE) criteria. 32 Fig. 2 describes our judgements about each “risk of bias” 93 
item presented as percentages across all included studies. 94 
The included RCTs compared different active treatments: either different drugs or 95 
different regimens of the same drug. None compared an active treatment to placebo. 96 
In total, we identified five different antifungal agents and grouped the data into 13 97 
comparisons (Fig. 3).  98 
Terbinafine versus griseofulvin 99 
Pooled data of five RCTs demonstrated that there was no significant difference 100 
between terbinafine (2-4 weeks) and griseofulvin (8 weeks) to achieve complete cure 101 
of Trichophyton or Microsporum infections after a 12- to 24-week follow-up (risk ratio 102 
[RR] 1.08, 95% confidence interval (CI) 0.94 to 1.24; 477 participants; I2=41%). 7, 14, 16, 103 
19, 26 We performed subgroup analyses according to the species causing the infection. 104 
A meta-analysis of three RCTs revealed that terbinafine (for 4 weeks) and griseofulvin 105 
(for 8 weeks) had similar effects in terms of complete cure of Trichophyton infections 106 
after a 12- to 24-week follow-up (RR 1.06; 95% CI 0.98 to 1.15; 328 participants; I2=0%). 107 
14, 16, 19 Additionally, a small RCT found no significant difference between terbinafine 108 
(for 4 weeks) and griseofulvin (for 8 weeks) to achieve complete cure of Microsporum 109 
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infections after a 24-week follow-up (RR: 0.45; 95% CI 0.15 to 1.35; 21 participants). 14  110 
Pooled data of two RCTs demonstrated no significant difference between terbinafine 111 
(6 weeks) and griseofulvin (6 weeks) for achieving complete cure of Trichophyton 112 
infections after a 10-week follow-up (RR 1.18; 95% CI 0.74 to 1.88; 1006 participants; 113 
I2=85%). 10, 23 However, subgroup analysis revealed that terbinafine was better than 114 
griseofulvin in terms of complete cure of T. tonsurans infections (RR 1.47; 95% CI 1.22 115 
to 1.77; 764 participants). 10, 23 In children infected with T. violaceum, terbinafine and 116 
griseofulvin had similar effects to achieve complete cure (RR 0.91; 95% CI 0.68 to 1.24; 117 
242 participants). 10, 23 118 
These two RCTs further compared medium-term (6-8 weeks) terbinafine with 119 
griseofulvin (6-12 weeks) in children with Microsporum infections. 10, 23 A meta-120 
analysis of the two studies showed that griseofulvin was better than medium-term 121 
terbinafine for achieving complete cure of Microsporum infections after a 10- to 16-122 
week follow-up (RR 0.68; 95% CI 0.53 to 0.86; 334 participants; I2=0%). In addition, one 123 
of the two RCTs also compared long-term (10-12 weeks) terbinafine with griseofulvin 124 
(for 12 weeks) for treating Microsporum infections. 23 It demonstrated that griseofulvin 125 
was better than long-term terbinafine in terms of complete cure after a 16-week 126 
follow-up (RR 0.51; 95% CI 0.34 to 0.76; 95 participants). 127 
A large RCT reported that 9.2% of participants in the terbinafine group and 8.3% in the 128 
griseofulvin group experienced adverse events (RR 1.11; 95% CI 0.79 to 1.57; 1549 129 
participants). 10 The most frequent adverse events were headache, pyrexia, cough, 130 
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nasopharyngitis and vomiting. 10 Severe adverse events were rare (0.6% in both groups; 131 
RR 0.97; 95% CI 0.24 to 3.88; 1549 participants). 10 Another RCT found more adverse 132 
events in both terbinafine and griseofulvin groups (33.8% vs. 24.3%), but no significant 133 
difference was identified between the two groups (RR 1.39; 95% CI 0.83 to 2.34; 147 134 
participants). 14 Other RCTs reported good tolerability for both terbinafine and 135 
griseofulvin because there were no or few adverse events. 7, 9, 19, 21, 26  136 
Different treatment durations of terbinafine 137 
Pooled data of four RCTs 11, 13, 18, 22 demonstrated that a 4-week duration of terbinafine 138 
was better than 1 to 2-weeks of terbinafine to achieve complete cure of Trichophyton 139 
and Microsporum infections after a 12- to 20-week follow-up (RR 0.73; 95% CI 0.62 to 140 
0.86; 552 participants; I2=18%). However, in another RCT 23, no significant difference 141 
was found between medium-term terbinafine (6-8 weeks) and long-term terbinafine 142 
(10-12 weeks) for complete cure of Trichophyton or Microsporum infections after a 16-143 
week follow-up (RR 1.45; 95% CI 0.97 to 2.17; 135 participants). 144 
Five RCTs 9, 11, 13, 17, 18 reported on adverse events. Briefly, all adverse effects (e.g., 145 
headache, nausea, urticaria, and lack of appetite) were mild and comparable between 146 
the intervention groups.  147 
Standard dose terbinafine vs. double dose terbinafine 148 
According to the limited evidence from a small RCT 31, a standard dose (body weight 149 
10–20 kg, 62.5 mg; 20–40 kg, 125 mg; > 40 kg, 250 mg) of terbinafine and a double 150 
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dose of terbinafine (once daily for 1 week followed by a 3-week period without 151 
treatment, two cycles in both groups) had similar effects in terms of complete cure of 152 
Microsporum infections after a 20-week follow-up (RR 1.2; 95% CI 0.72 to 1.76; 42 153 
participants). Adverse effects were not addressed.  154 
Itraconazole versus griseofulvin 155 
Pooled data of two small RCTs identified no significant difference between itraconazole 156 
(for 2-6 weeks) and griseofulvin (for 6 weeks) to achieve a complete cure of 157 
Trichophyton or Microsporum infections after a 12- to 14-week follow-up (RR 0.92; 95% 158 
CI 0.81 to 1.05; 134 participants; I2=0%). 16, 24   159 
In these two RCTs, no adverse events were identified in the itraconazole group; five 160 
cases of nausea 16, 24 and three cases of gastric problems 16 were found in the 161 
griseofulvin group. 162 
Itraconazole versus terbinafine 163 
A meta-analysis of two small RCTs showed that itraconazole（2-3 weeks） and 164 
terbinafine (for 2-3 weeks) had similar effects to achieve a complete cure of 165 
Trichophyton infections after a 12-week follow-up (RR 0.93; 95% CI 0.72 to 1.19; 160 166 
participants; I2=35%). 16, 20 167 
One RCT reported that two participants in the itraconazole group experienced urticaria 168 
and one participant in the terbinafine group experienced fever, body aches and vertigo. 169 
20   170 
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Ketoconazole versus griseofulvin  171 
One study indicated that ketoconazole (for 12 weeks) appeared to be less effective 172 
than griseofulvin (for 12 weeks) for achieving complete cure of Trichophyton infections 173 
at the end of 12 weeks of therapy (RR 0.76; 95% CI 0.62 to 0.94; 62 participants). 15 174 
However, when the treatment duration was extended up to a maximum of 26 weeks 175 
for participants who had not achieved a complete cure by 12 weeks, the effect of 176 
ketoconazole and griseofulvin seemed to be similar (RR 0.95; 95% CI 0.83 to 1.07; 62 177 
participants). Another study demonstrated that ketoconazole (12 weeks) and 178 
griseofulvin (12 weeks) achieved a similar complete cure of Trichophyton or 179 
Microsorum infections at the end of 12 weeks of therapy (RR 0.89; 95% CI 0.57 to 1.39; 180 
79 participants). 29  181 
Four RCTs reported the adverse events regarding this comparison. Adverse events in 182 
both ketoconazole and griseofulvin groups were mild and rare. Ketoconazole use was 183 
associated with two cases of abdominal pain 30, one case of urticaria 30, one case of 184 
nausea 29; griseofulvin in one case was associated with a two-fold increase in serum 185 
alanine aminotransferase. 25 186 
Fluconazole versus griseofulvin 187 
Pooled data of three RCTs 8, 12, 16 showed that fluconazole (2-4 weeks) and griseofulvin 188 
(2-4 weeks) had similar effects in achieving complete cure of Trichophyton or 189 
Microsporum infections after an 8- to 12-week follow-up (RR 0.92; 95% CI 0.81 to 1.05; 190 
615 participants; I2=0%). One RCT 12 showed that fluconazole (6 weeks) and 191 
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griseofulvin (6 weeks) were similarly effective in achieving complete cure of 192 
Trichophyton infection after 12-week follow-up (RR 1.06; 95% CI 0.77 to 1.46; 361 193 
participants). Adverse effects were not reported. 194 
Fluconazole versus terbinafine 195 
A small RCT 16 found no significant difference between fluconazole (2-3 weeks) and 196 
terbinafine (2-3 weeks), with respect to the outcome of complete cure of Trichophyton 197 
infections, at the end of 12-week follow-up (RR 0.87; 95% CI 0.75 to 1.01; 100 198 
participants). Adverse events were not addressed. 199 
Fluconazole versus itraconazole 200 
The same RCT 16 also found no significant difference between fluconazole (2-3 weeks) 201 
and itraconazole (2-3 weeks) in achieving complete cure of Trichophyton infections at 202 
the end of 12-week follow-up (RR 1.00 95% CI 0.83 to 1.20; 100 participants). Adverse 203 
events were not reported. 204 
Different dosages of fluconazole 205 
A small RCT 28 compared different dosages of fluconazole (1.5 mg/kg/d, 3.0 mg/kg/d, 206 
and 6.0 mg/kg/d; each for 20 days) in 41 children infected with Trichophyton species. 207 
Only 27 participants completed this study and the details of drop-outs in each 208 
intervention group were unclear. We used intention-to-treat (ITT) analyses and found 209 
that higher doses appeared to result in more cures than lower doses after 4-month 210 
follow-up (17% in the 1.5mg/kg/d group, 40% in the 3.0 mg/kg/d group, and 57% in 211 
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the 6.0 mg/kg/d group); however, none of these comparisons reached statistical 212 
significance (3.0 mg/kg/d vs. 1.5 mg/kg/d: RR 2.40, 95% CI 0.59 to 9.82; 6.0 mg/kg/d 213 
vs. 1.5 mg/kg/d: RR 3.43, 95% CI 0.89 to 13.15; 6.0 mg/kg/d vs. 3.0 mg/kg/d: RR 1.43, 214 
95% CI 0.66 to 3.08). Adverse effects were not reported. 215 
Short-term fluconazole versus medium-term fluconazole 216 
Based on one RCT 12, short-term fluconazole (3 weeks) and medium-term fluconazole 217 
(6 weeks) made no significant difference in terms of complete cure of T. tonsurans and 218 
M. canis infections at the end of 10-week follow-up (RR 0.88; 95% CI 0.68 to 1.14; 491 219 
participants). Adverse effects were not reported.  220 
DISCUSSION 221 
Current evidence supports that both griseofulvin and terbinafine are an effective first-222 
line choice for children with tinea capitis infected with Trichophyton or Microsporum 223 
species; however, terbinafine may be a better choice for those infected with T. 224 
tonsurans, while griseofulvin may be a better choice for those infected with M. canis. 225 
We did not find any evidence to support a difference in terms of adherence between 226 
four weeks of terbinafine versus eight weeks of griseofulvin. 227 
Limited evidence demonstrates that terbinafine, itraconazole and fluconazole appear 228 
to have similar effects for Trichophyton species infections, whereas ketoconazole may 229 
be less effective. There is some evidence to suggest that fluconazole is comparable to 230 
griseofulvin, especially for Trichophyton species infections. The majority of the current 231 
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literature deals with griseofulvin and terbinafine and there are few large, long term 232 
well-conducted trials. Future studies should be designed with attention to the merits, 233 
optimal dosages and durations of newer antifungals (e.g., itraconazole and fluconazole) 234 
both in comparison to each other and to griseofulvin or terbinafine. 235 
Our review found that, while not all treatments for tinea capitis are available in 236 
pediatric formulations, the adverse events of griseofulvin, terbinafine, itraconazole, 237 
fluconazole and ketoconazole for treating children with tinea capitis were mild and 238 
reversible. Adverse events were comparable between terbinafine and griseofulvin. 239 
However, readers should keep in mind that RCTs with small study populations and or 240 
relatively short duration are not optimal for studying rare or long-term adverse events. 241 
Ketoconazole has been linked to adrenal insufficiency and liver toxicity including cases 242 
of death 33-35.  Reports of such adverse effects were not identified in the studies 243 
included in our review. It is notable that oral ketoconazole has been withdrawn from 244 
use in the United Kingdom and Europe since 2013. 1 In addition, both the U.S. Food 245 
and Drug Administration (FDA) 34 and Health Canada 35 have recently issued releases 246 
describing labelling changes for oral ketoconazole, and risks of potentially fatal liver 247 
damage. The FDA guidance recommended the use of oral ketoconazole only for 248 
“serious fungal infections when no other antifungal therapies are available”. 34 Similarly, 249 
Health Canada recommended oral ketoconazole only for “the treatment of serious or 250 
life-threatening fungal diseases”. 35 251 
The clinical heterogeneity between the studies in terms of the population and type of 252 
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causative organism, may have contributed to observed statistical heterogeneity in 253 
some of our comparisons, when we pooled the data from different studies by meta-254 
analysis. As a consequence of variation between the study populations, in individual 255 
patients, the most appropriate treatment may differ from treatments identified as 256 
most effective in this review. All of the included RCTs were at unclear or high risk of 257 
bias and the overall quality of the body of evidence was at best moderate, and for most 258 
outcomes, low quality (GRADE). 32 In the absence of further information being 259 
obtainable, our assessment of risk of bias was based on the published manuscripts, 260 
and the results were inevitably influenced by the reporting quality of these primary 261 
studies.  262 
Some questions remain about whether there are advantages to the newer and 263 
relatively more expensive antifungals such as terbinafine, itraconazole, and 264 
fluconazole, both in comparison to each other and to griseofulvin. Further research is 265 
required regarding appropriate pediatric formulations and adherence to treatment 266 
(which may be needed over several weeks) in children. Patient-reported outcomes 267 
such as quality of life are important for evidence-based clinical decisions and need to 268 
be addressed in future studies. Clinical studies should conform to the Consolidated 269 
Standards of Reporting Trials (CONSORT) 2010 statement, to improve the reporting 270 




We thank the Cochrane Skin Group for their editorial support in producing this 273 




CI: confidence interval 276 




1. Fuller LC, Barton RC, Mohd Mustapa MF, Proudfoot LE, Punjabi SP , Higgins EM. 279 
British Association of Dermatologists' guidelines for the management of tinea capitis 280 
2014. Br J Dermatol 2014;171:454-63. 281 
2. Ginter‐Hanselmayer G, Weger W, Ilkit M , Smolle J. Epidemiology of tinea capitis in 282 
Europe: current state and changing patterns. Mycoses 2007;50:6-13. 283 
3. Sarabi K , Khachemoune A. Tinea capitis: a review. Dermatol Nurs 2007;19:525-30. 284 
4. Chen X, Jiang X, Yang M, Gonzalez U, Lin X, Hua X et al. Systemic antifungal therapy 285 
for tinea capitis in children. Cochrane Database Syst Rev 2016;5:CD004685. 286 
5. Higgins JPT , Green S. Cochrane Handbook for Systematic Reviews of Interventions 287 
Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available 288 
from www.cochrane-handbook.org. 289 
6. Review Manager (RevMan). Copenhagen: The Nordic Cochrane Centre, The 290 
Cochrane Collaboration; 2014. 291 
7. Cáceres-Ríos H, Rueda M, Ballona R , Bustamante B. Comparison of terbinafine and 292 
griseofulvin in the treatment of tinea capitis. J Am Acad Dermatol 2000;42:80-4. 293 
8. Dastghaib L, Azizzadeh M , Jafari P. Therapeutic options for the treatment of tinea 294 
capitis: griseofulvin versus fluconazole. J Dermatol Treat 2005;16:43-6. 295 
9. Deng S, Hu H, Abliz P, Wan Z, Wang A, Cheng W et al. A random comparative study 296 
of terbinafine versus griseofulvin in patients with tinea capitis in Western China. 297 
Mycopathologia 2011;172:365-72. 298 
19 
 
10. Elewski BE, Caceres HW, DeLeon L, El Shimy S, Hunter JA, Korotkiy N et al. 299 
Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children 300 
with tinea capitis: results of two randomized, investigator-blinded, multicenter, 301 
international, controlled trials. J Am Acad Dermatol 2008;59:41-54. 302 
11. Filho ST, Cuce LC, Foss NT, Marques SA , Santamaria JR. Efficacy, safety and 303 
tolerability of terbinafine for Tinea capitis in children: Brazilian multicentric study with 304 
daily oral tablets for 1,2 and 4 weeks. J Eur Acad Dermatol Venereol 1998;11:141-6. 305 
12. Foster KW, Friedlander SF, Panzer H, Ghannoum MA , Elewski BE. A randomized 306 
controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea 307 
capitis. J Am Acad Dermatol 2005;53:798-809. 308 
13. Friedlander SF, Aly R, Krafchik B, Blumer J, Honig P, Stewart D et al. Terbinafine in 309 
the treatment of Trichophyton tinea capitis: a randomized, double-blind, parallel-310 
group, duration-finding study. Pediatrics 2002;109:602-7. 311 
14. Fuller LC, Smith CH, Cerio R, Marsden RA, Midgley G, Beard AL et al. A randomized 312 
comparison of 4 weeks of terbinafine vs. 8 weeks of griseofulvin for the treatment of 313 
tinea capitis. Br J Dermatol 2001;144:321-7. 314 
15. Gan VN, Petruska M , Ginsburg CM. Epidemiology and treatment of tinea capitis: 315 
ketoconazole vs. griseofulvin. Pediatr Infect Dis J 1987;6:46-9. 316 
16. Gupta AK, Adam P, Dlova N, Lynde CW, Hofstader S, Morar N et al. Therapeutic 317 
options for the treatment of tinea capitis caused by trichophyton species: griseofulvin 318 
versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole. 319 
20 
 
Pediatr Dermatol 2001;18:433-8. 320 
17. Hamm H, Schwinn A, Bräutigam M , Weidinger G. Short duration treatment with 321 
terbinafine for tinea capitis caused by Trichophyton or Microsporum species. The 322 
Study Group. Br J Dermatol 1999;140:480-2. 323 
18. Haroon TS, Hussain I, Aman S, Jahangir M, Kazmi AH, Sami AR et al. A randomized 324 
double-blind comparative study of terbinafine for 1, 2, and 4 weeks in tinea capitis. Br 325 
J Dermatol 1996;135:86-8. 326 
19. Haroon TS, Hussain I, Aman S, Nagi AH, Ahmad I, Zahid M et al. A randomized 327 
double-blind comparative study of terbinafine and griseofulvin in tinea capitis. J 328 
Dermatol Treat 1995;6:167-9. 329 
20. Jahangir M, Hussain I, Ul Hassan M , Haroon TS. A double-blind, randomized, 330 
comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis. Br J 331 
Dermatol 1998;139:672-4. 332 
21. Khan SU, Khan AR , Wazir SM. Efficacy of terbinafine vs. griseofulvin in tinea capitis 333 
in the northern areas of Pakistan. JPAD 2011;21:281-4. 334 
22. Kullavanijaya P, Reangchainam S , Ungpakorn R. Randomized single-blind study of 335 
efficacy and tolerability of terbinafine in the treatment of tinea capitis. J Am Acad 336 
Dermatol 1997;37:272-3.  337 
23. Lipozencic J, Skerlev M, Orofino-Costa R, Zaitz VC, Horvath A, Chouela E et al. A 338 
randomized, double-blind, parallel-group, duration-finding study of oral terbinafine 339 
and open-label, high-dose griseofulvin in children with tinea capitis due to 340 
21 
 
Microsporum species. Br J Dermatol 2002;146:816-23. 341 
24. López-Gómez S, Del Palacio A, Van Cutsem J, Soledad Cuétara M, Iglesias L , 342 
Ródriguez-Noriega A. Itraconazole versus griseofulvin in the treatment of tinea capitis: 343 
a double-blind randomized study in children. Int J Dermatol 1994;33:743-7.  344 
25. Martínez-Roig A, Torres-Rodríguez JM , Bartlett-Coma A. Double-blind study of 345 
ketoconazole and griseofulvin in dermatophytoses. Pediatr Infect Dis J 1988;7:37-40. 346 
26. Memisoglu HR, Erboz S, Akkaya S, Akan T, Aksungur VL, Ünal I et al. Comparative 347 
study of the efficacy and tolerability of 4 weeks of terbinafine therapy with 8 weeks of 348 
griseofulvin therapy in children with tinea capitis. J Dermatol Treat 1999;10:189-93. 349 
27. Rademaker M , Havill S. Griseofulvin and terbinafine in the treatment of tinea 350 
capitis in children. N Z Med J 1998;111:55-7. 351 
28. Solomon BA, Collins R, Sharma R, Silverberg N, Jain AR, Sedgh J et al. Fluconazole 352 
for the treatment of tinea capitis in children. J Am Acad Dermatol 1997;37:274-5. 353 
29. Tanz RR, Hebert AA , Esterly NB. Treating tinea capitis: Should ketoconazole replace 354 
griseofulvin? J Pediatr 1988;112:987-91. 355 
30. Tanz RR, Stagl S , Esterly NB. Comparison of ketoconazole and griseofulvin for 356 
treatment of tinea capitis in childhood: a preliminary study. Pediatr Emerg Care 357 
1985;1:16-8. 358 
31. Ungpakorn R, Ayutyanont T, Reangchainam S , Supanya S. Treatment of 359 




32. Schünemann H., Brożek J., Guyatt G. & Oxman A., editors. GRADE handbook for 362 
grading quality of evidence and strength of recommendations. The GRADE Working 363 
Group. http://www.guidelinedevelopment.org/handbook (Accessed Jun 23, 2016). 364 
33. Elewski BE. Tinea capitis: a current perspective. J Am Acad Dermatol 2000;42:1-24. 365 
34. U.S. Food and Drug Administration. Nizoral (ketoconazole) oral tablets: Drug Safety 366 
Communication - Prescribing for unapproved uses including skin and nail infections 367 
continues; linked to patient death. FDA Medwatch. May 19, 2016. 368 
http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedi369 
calproducts/ucm502073.htm (Accessed Aug 6, 2016). 370 
35. Public Communication - Health Canada Endorsed Important Safety Information on 371 
KETOCONAZOLE. Health Canada. Jun 19, 2013. http://healthycanadians.gc.ca/recall-372 
alert-rappel-avis/hc-sc/2013/34177a-eng.php (Accessed Aug 6, 2016). 373 
36. Schulz KF, Altman DG, Moher D , Consort Group. CONSORT 2010 Statement: 374 
updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.  375 
23 
 
Figure legend 376 
Fig 1. Tinea capitis. PRISMA (Preferred Reporting Items for Systematic Reviews and 377 
Meta-Analyses) diagram of study flow. 378 
Fig 2. Tinea capitis. Risk of bias graph 379 
Fig 3. Tinea capitis. The construction of study comparisons 380 
